Nearly 250 substances are being researched and developed preclinically for the treatment of ALS, HD, and MG (Table in the Supporting Information lists these compounds, along with their suggestive mechanism of action, therapy type, and the company developing them). The vast majority (74%) of these substances are for the treatment of ALS but therapies for the treatment of HD (18%) and MG (8%) are also in the development pipeline (Table in the Supporting Information). A wide range of therapies are being investigated. Small molecule drugs dominate in the total number of drug candidates followed by gene, antibody, RNA, antisense oligonucleotide (ASO), and stem cell therapies, amongst others (Figure ). Small molecule drugs make up about 50% of the drug candidates for ALS and MG, in contrast to only 10% for HD where gene therapy, RNA interference agents, and other biologic treatments dominate (Figure ).